Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Menarini Group

http://www.menarini.com/

Latest From Menarini Group

Driving Menarini's Future With Decisive Steps

Two years into her tenure as the head of Menarini, Elcin Barker Ergun has already inked two major cancer deals with the acquisition of Stemline and a key licensing pact with Radius Health. The future for the Italian group is bright, she explained to Scrip in an exclusive interview.

Leadership Business Strategies

Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy

Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.

Deals Cancer

Finance Watch: $135m In Venture Capital Will Fund Amylyx’s Late-Stage ALS Drug

Private Company Edition: Amylyx will use its new cash to run a Phase III trial and submit applications seeking EU and Canadian approvals of AMX0035, but US filing plans based on prior Phase II/III data are less clear. Also, three VC firms raised new funds targeting biopharma and other investments.

Financing Innovation

Deal Watch: Pfizer Invests In Spero, Parexel Trades Hands

EQT and Goldman Sachs to pay $8.5bn in Parexel’s second private equity buyout in four years.

Deal Watch Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
    • Glucose Testing
    • Hematology, Coagulation
    • Urine-based Testing
UsernamePublicRestriction

Register